Preliminary Data Suggest Spasticity May Be Reduced in RRMS Patients Who Transitioned to COPAXONE

Teva Pharmaceutical announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Copaxone (glatiramer acetate injection) from interferon-beta treatment.
Benzinga